BioCentriq
A cell and gene therapy contract development and manufacturing organization (CDMO) that specializes in process development and clinical manufacturing.
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor | €0.0 | round | |
| investor | €0.0 | round | |
* | N/A | N/A | Series A |
| Total Funding | 000k | ||
Related Content
BioCentriq is a contract development and manufacturing organization (CDMO) specializing in cell and gene therapy. The company was founded in 2019 and is headquartered in Princeton, New Jersey, with multiple manufacturing facilities in the state.
BioCentriq offers a comprehensive suite of services that span the entire lifecycle of cell and gene therapy development, from early-stage process development and optimization to clinical-scale and commercial manufacturing. The company works with a diverse range of clients, including emerging biotech startups and established pharmaceutical companies, to help them accelerate the translation of their innovative therapies from the laboratory to the clinic. Its business model is centered on providing collaborative, full-service support, acting as an extension of its clients' own teams. Revenue is generated through fee-for-service contracts for its development and manufacturing services.
Operating in the rapidly growing cell and gene therapy market, BioCentriq has positioned itself as a key player by combining a specialized focus with a commitment to quality and patient-centricity. The company has recently secured significant Series A funding, which is being used to expand its operational capacity and enhance its service offerings to meet the increasing demand for advanced therapy manufacturing.
Keywords: cell therapy, gene therapy, CDMO, clinical manufacturing, process development, autologous therapy, allogeneic therapy, cell banking, biomanufacturing, life sciences